Clinical Ovarian and Other Gynecologic Cancer最新文献_第4页

Should Dose-dense Paclitaxel in Combination With Carboplatin Be the New Standard for Treatment for Suboptimally Debulked Patients or Patients Treated With Neoadjuvant Chemotherapy? 剂量密集的紫杉醇联合卡铂是否应该成为治疗亚理想减积患者或接受新辅助化疗患者的新标准?

Clinical Ovarian and Other Gynecologic Cancer Pub Date : 2012-12-01 DOI: 10.1016/j.cogc.2013.12.002

Marilyn Huang, Robert L. Coleman

引用次数: 0

Is There a Role for Bevacizumab in the Primary Treatment of Advanced Ovarian Cancer Off-Protocol? 贝伐单抗在晚期卵巢癌非方案的初级治疗中有作用吗?

Clinical Ovarian and Other Gynecologic Cancer Pub Date : 2012-12-01 DOI: 10.1016/j.cogc.2013.12.003

Jane L. Meisel, Paul Sabbatini

引用次数: 0

Chemotherapy Treatment Patterns in Elderly Patients Initially Diagnosed With Advanced Ovarian Cancer 早期诊断为晚期卵巢癌的老年患者的化疗模式

Clinical Ovarian and Other Gynecologic Cancer Pub Date : 2012-12-01 DOI: 10.1016/j.cogc.2013.02.001

Scott J. Johnson , Rachael A. Sorg , Rohit D. Borker , Mei Sheng Duh

{"title":"Chemotherapy Treatment Patterns in Elderly Patients Initially Diagnosed With Advanced Ovarian Cancer","authors":"Scott J. Johnson , Rachael A. Sorg , Rohit D. Borker , Mei Sheng Duh","doi":"10.1016/j.cogc.2013.02.001","DOIUrl":"10.1016/j.cogc.2013.02.001","url":null,"abstract":"<div><h3>Background</h3><p>Over the past decade, chemotherapy treatment for patients with advanced ovarian cancer has expanded, with platinum-based and taxane therapy remaining the backbone. Elderly patients have received little attention, and less is known about the variation and duration of agents elderly women receive for first-line, maintenance, and second-line therapy.</p></div><div><h3>Patients and Methods</h3><p>Using SEER linked to Medicare claims data, we identified a cohort of women (older than 65 years) with advanced epithelial ovarian cancer who received first-line and/or maintenance therapy between 2003-2009. Over the same period, we identified women who received second-line therapy. We examined the variety of cytotoxic regimens and duration of therapy.</p></div><div><h3>Results</h3><p>In the patient group, 10,695 patients were eligible for chemotherapy, and 5357 had evidence of receiving any chemotherapy. The first-line sample included 2509 patients, the maintenance sample included 306 patients, and the second-line sample included 1890 patients. Among first-line patients, paclitaxel and carboplatin was the most common regimen. Approximately half of the patients did not successfully complete first-line treatment. Of those eligible for maintenance therapy, about one-quarter of the patients initiated a maintenance regimen, and approximately 10% of those who initiated maintenance therapy completed at least 40 weeks. The most common second-line treatment included platinum-based and taxane therapy, if the patient was platinum-sensitive, or a single-agent anthracycline therapy otherwise.</p></div><div><h3>Conclusion</h3><p>Additional research should address low first-line treatment completion rates. Most patients eligible for maintenance therapy do not initiate it, and multiple treatment strategies predominate in second-line therapy. There remains a substantial unmet need in therapy options for ovarian cancer.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"5 2","pages":"Pages 67-77.e1"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2013.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78915778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Role of Anti-Müllerian Hormone in Diagnosing Granulosa Cell Tumor: A Case Report 抗<s:1>勒氏激素在颗粒细胞瘤诊断中的作用1例报告

Clinical Ovarian and Other Gynecologic Cancer Pub Date : 2012-12-01 DOI: 10.1016/j.cogc.2012.12.001

Aarti Umranikar , Mili Saran , Nick Brook , Neeta Singh , Darren Fowler , Ying Cheong

引用次数: 1

Immune Surveillance Tissue Antigen Profiling in Advanced Ovarian Cancer 晚期卵巢癌的免疫监测组织抗原谱分析

Clinical Ovarian and Other Gynecologic Cancer Pub Date : 2012-12-01 DOI: 10.1016/j.cogc.2012.09.001

Patrick J. Stiff , Ronald K. Potkul , Girish Venkataraman , Payal Sojitra , Maureen L. Drakes

{"title":"Immune Surveillance Tissue Antigen Profiling in Advanced Ovarian Cancer","authors":"Patrick J. Stiff , Ronald K. Potkul , Girish Venkataraman , Payal Sojitra , Maureen L. Drakes","doi":"10.1016/j.cogc.2012.09.001","DOIUrl":"10.1016/j.cogc.2012.09.001","url":null,"abstract":"<div><h3>Aim</h3><p>A knowledge of tumor-related antigens associated with survival of patients with ovarian cancer could contribute toward the development of tests for early diagnosis and could provide targets for the design of novel immunotherapy for advanced ovarian cancer. We conducted a pilot immunohistochemical study to determine a group of antigens in ovarian tumor masses that correlate with survival.</p></div><div><h3>Methods</h3><p>We studied T-cell subsets and tumor antigens on 69 cases of paraffin-embedded patient blocks to determine if any correlated with survival in this disease. These were identified by staining for CD3, CD8, FoxP3, New York esophageal-1 (NY-ESO-1), melanoma-associated antigen (MAGE) A, cyclin E, and intercellular adhesion molecule-1 (ICAM-1) antigens in tissue when using specific antibodies.</p></div><div><h3>Results</h3><p>Study patients had a median age of 58 years and an overall survival of 31%. Infiltrating CD3<sup>+</sup> T cells correlated with improved survival of patients (<em>P</em> = .002, log-rank test). The frequency of cyclin E, ICAM-1, CD8, and FoxP3 expressing cells were not statistically associated with survival. MAGE-A was expressed in 10 (45%) of 22 whole-tissue sections studied, and this expression correlated with decreased survival (<em>P</em> = .03, log-rank test). The presence and frequency of FoxP3 infiltrating suppressor T cells was associated with high-stage disease (<em>P</em> = .02, χ<sup>2</sup> test; <em>P</em> = .03, Wilcoxon test).</p></div><div><h3>Conclusions</h3><p>The significance of CD3 T cells in tumor tissue may be primarily associated with an active antitumor immune response. MAGE-A family members may represent successful antigens for immunotherapeutic targeting in ovarian cancer.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"5 2","pages":"Pages 78-86"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2012.09.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77518395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Paraneoplastic Anti-N-Methyl-D-Apartate-Receptor Encephalitis Associated With an Immature Teratoma 与未成熟畸胎瘤相关的副肿瘤抗n -甲基- d -分离物受体脑炎

Clinical Ovarian and Other Gynecologic Cancer Pub Date : 2012-12-01 DOI: 10.1016/j.cogc.2013.02.002

A. Mitch Dizon , Karen L. Samples , Kristopher J. Kimball , Larry C. Kilgore

引用次数: 1

Platelet-Derived Growth Factor Gene Polymorphisms in Patients With Ovarian Cancer 卵巢癌患者血小板衍生生长因子基因多态性

Clinical Ovarian and Other Gynecologic Cancer Pub Date : 2012-06-01 DOI: 10.1016/j.cloc.2012.02.020

Christine Vestergaard Madsen , Karina Dahl Steffensen , Marianne Waldstrøm , Rikke Fredslund Andersen , Charlotte Hasselholt Søgaard , Ivan Brandslund , Anders Jakobsen

{"title":"Platelet-Derived Growth Factor Gene Polymorphisms in Patients With Ovarian Cancer","authors":"Christine Vestergaard Madsen , Karina Dahl Steffensen , Marianne Waldstrøm , Rikke Fredslund Andersen , Charlotte Hasselholt Søgaard , Ivan Brandslund , Anders Jakobsen","doi":"10.1016/j.cloc.2012.02.020","DOIUrl":"10.1016/j.cloc.2012.02.020","url":null,"abstract":"<div><h3>Introduction</h3><p>New reliable and validated markers are desirable in the treatment of ovarian cancer. The platelet-derived growth factor (PDGF) system plays an important role in tumor growth and angiogenesis, and high expression of PDGF/PDGF receptor (PDGFR) has been reported in ovarian cancer. Single nucleotide polymorphisms (SNPs) within a gene may be important for the function of the protein. This had led to the hypothesis that SNPs within the PDGF system could have clinical relevance as prognostic biomarkers in ovarian cancer.</p></div><div><h3>Methods</h3><p>The study included hypothesis-generating patient material from 170 patients with histologically verified epithelial ovarian cancer in which 5 tagging SNPs in the promoter region of the <em>PDGF-AA</em>, <em>PDGF-BB, PDGFR-α,</em> and <em>PDGFR-β</em> genes were analyzed by means of SNaPshot Multiplex (Applied Biosystems, Carlsbad, CA) and sequencing methods. The results were validated in an independent second cohort of 85 patients.</p></div><div><h3>Results</h3><p>In the hypothesis-generating study, survival analyses were made for all 5 SNPs. <em>PDGF-AA 1589 G/T</em> genotype was found to be associated with overall survival in univariate analysis (<em>P</em> = .03), with a clear trend seen in Cox multivariate analysis (<em>P</em> = .12; hazard ratio, 0.75). However, the suggested prognostic importance of <em>PDGF-AA 1589 G/T</em> was not confirmed in the second cohort.</p></div><div><h3>Conclusion</h3><p>Tagging SNPs in the promoter region of the <em>PDGF-AA, PDGF-BB, PDGFR-α</em>, and <em>PDGFR-β</em> genes, as evaluated here, are not likely to be of prognostic importance in patients with ovarian cancer.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"5 1","pages":"Pages 10-16"},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cloc.2012.02.020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80302009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Unusual Collision Tumor of Ovary: Endometrioid Adenocarcinoma and Teratoma 卵巢异常碰撞瘤:子宫内膜样腺癌和畸胎瘤

Clinical Ovarian and Other Gynecologic Cancer Pub Date : 2012-06-01 DOI: 10.1016/j.cloc.2011.12.001

Eliyaz Ahmed, Shatrughan P. Sah, Anilkumar Adikesavalu, Krishnaswamy Madhavan, Khalil Razvi

引用次数: 5

Ovarian Endometrioid Adenocarcinoma With a Yolk Sac Tumor Component in a Postmenopausal Woman: Case Report and Review of the Literature 绝经后妇女卵巢子宫内膜样腺癌伴卵黄囊肿瘤成分:病例报告及文献回顾

Clinical Ovarian and Other Gynecologic Cancer Pub Date : 2012-06-01 DOI: 10.1016/j.cogc.2012.05.003

Jacopo Giuliani , Marina Marzola , Pamela Pizzutilo , Ruby Martinello , Andrea Marzola , Monica Indelli , Antonio Frassoldati

引用次数: 6

A New Era for Clinical Ovarian and Other Gynecologic Cancer 临床卵巢癌和其他妇科肿瘤的新时代

Clinical Ovarian and Other Gynecologic Cancer Pub Date : 2012-06-01 DOI: 10.1016/j.cogc.2012.06.002

Ronald D. Alvarez (Editor-in-Chief)

引用次数: 0